VETARYS
@vetarys.com
Vetarys is focused on improving the lives of companion animals through the development of innovative biotherapeutics targeting cancer and osteoarthritis. The company’s approach centers on translating advances in human medicine and immunology into practical veterinary therapies that address major unmet needs in animal health. In osteoarthritis, Vetarys is pursuing disease-modifying and potentially regenerative treatments designed to go beyond pain management. In oncology, the company aims to expand access to next-generation immunotherapies for companion animals, building on decades of progress in human cancer treatment.
VETARYS's Company Logos
VETARYS's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#000435
Stratos
0, 4, 53
235, 100, 10
100, 92, 0, 79
#F7F3EF
Spring Wood
247, 243, 239
30, 33, 95
0, 2, 3, 3
About VETARYS
Vetarys is a pioneering company in veterinary medicine committed to enhancing the lives of pets suffering from chronic conditions, such as osteoarthritis and cancer. With a mission encapsulated in their slogan Pets Deserve Better Medicine, Vetarys is dedicated to developing innovative therapies that merge the rigor of human biotechnology with practical veterinary care. Their flagship development, the VTX-304 program, offers a bispecific antibody aimed at treating osteoarthritis by addressing pain and cartilage degradation, potentially leading to the first disease-modifying osteoarthritis drug in pets.
Additionally, their VTX-301/302 cancer program represents an advanced immunotherapy approach, designed to improve anti-tumor efficacy beyond traditional treatments. The leadership team at Vetarys comprises seasoned experts from veterinary and biopharmaceutical sectors, ensuring that their strategies are rooted in robust scientific and commercial principles. With a strong focus on unmet medical needs, Vetarys is reshaping the landscape of veterinary treatment, providing pet owners and veterinarians with effective tools to manage chronic illnesses in their beloved animals
